Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FPRX
  • CUSIP: N/A
  • Web: www.fiveprime.com
Capitalization:
  • Market Cap: $859.26 million
  • Outstanding Shares: 27,897,000
Average Prices:
  • 50 Day Moving Avg: $29.96
  • 200 Day Moving Avg: $36.84
  • 52 Week Range: $26.65 - $60.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.01
  • P/E Growth: 0.10
Sales & Book Value:
  • Annual Revenue: $34.31 million
  • Price / Sales: 24.27
  • Book Value: $12.80 per share
  • Price / Book: 2.33
Profitability:
  • EBIDTA: ($111,050,000.00)
  • Net Margins: -250.98%
  • Return on Equity: -21.81%
  • Return on Assets: -18.92%
Debt:
  • Current Ratio: 10.98%
  • Quick Ratio: 10.98%
Misc:
  • Average Volume: 292,148 shs.
  • Beta: 4.23
  • Short Ratio: 7
 
Frequently Asked Questions for Five Prime Therapeutics (NASDAQ:FPRX)

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.96) by $0.25. The firm earned $10.13 million during the quarter, compared to the consensus estimate of $6.05 million. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The firm's revenue for the quarter was up 55.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.49) EPS. View Five Prime Therapeutics' Earnings History.

Where is Five Prime Therapeutics' stock going? Where will Five Prime Therapeutics' stock price be in 2017?

7 brokers have issued 12 month target prices for Five Prime Therapeutics' shares. Their predictions range from $54.00 to $94.00. On average, they expect Five Prime Therapeutics' stock price to reach $65.20 in the next year. View Analyst Ratings for Five Prime Therapeutics.

What are analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:

  • 1. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)
  • 2. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (5/2/2017)
  • 3. Cowen and Company analysts commented, "We believe Five Prime has amongst the leading IO drug discovery platforms in the industry. The BMS partnership provides validation. Multiple clinical readouts in 2017 provide catalysts to drive value generation. Lead asset Cabira has significant potential in solid tumors, we expect FPA144 to succeed in FGFR2b+ gastric cancer (2019), and we see high POS for Cabira in PVNS. Initiating at Outperform." (3/24/2017)
  • 4. Instinet analysts commented, "We are initiating on Five Prime Therapeutics (FPRX) with a Buy rating and a $94, 12-month target price. We recommend owning FPRX shares ahead of potentially transformational mid-2017 readouts. We anticipate 2017 data from cabiralizumab and key competitors will further de-risk cabiralizumab's anti-CSF1R mechanism in immuno-oncology, define pivotal clinical paths, establish initial market opportunities, and differentiate its safety versus competitors." (3/1/2017)

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:

  • Lewis T. Williams M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Marc L. Belsky, Chief Financial Officer, Senior Vice President
  • Aron Marc Knickerbocker MBA, Chief Operating Officer, Director
  • Kevin Baker Ph.D., Senior Vice President, Development Sciences
  • Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer
  • Francis Willard Sarena J.D., Chief Strategy Officer and Secretary
  • Mark D. McDade, Lead Independent Director
  • Garry Nicholson, Director
  • Franklin M. Berger, Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

Who owns Five Prime Therapeutics stock?

Five Prime Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.02%), Creative Planning (0.02%) and Daiwa SB Investments Ltd. (0.02%). Company insiders that own Five Prime Therapeutics stock include Adage Capital Partners Gp Llc, Francis Willard Sarena, Franklin M Berger, Lewis T Williams, Marc Belsky, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

Who sold Five Prime Therapeutics stock? Who is selling Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Daiwa SB Investments Ltd.. Company insiders that have sold Five Prime Therapeutics stock in the last year include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Insider Buying and Selling for Five Prime Therapeutics.

Who bought Five Prime Therapeutics stock? Who is buying Five Prime Therapeutics stock?

Five Prime Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Financial Services Inc. and Creative Planning. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy Five Prime Therapeutics stock?

Shares of Five Prime Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of Five Prime Therapeutics stock can currently be purchased for approximately $29.85.


MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.20 (118.43% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Jefferies Group LLCReiterated RatingBuy$55.00MediumView Rating Details
3/24/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016Citigroup Inc.Initiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$48.00N/AView Rating Details
4/12/2016BMO Capital MarketsInitiated CoverageMarket Perform$50.00N/AView Rating Details
12/4/2015Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Earnings History by Quarter for Five Prime Therapeutics (NASDAQ FPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)
2017 EPS Consensus Estimate: ($4.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.97)($0.97)($0.97)
Q2 20171($1.03)($1.03)($1.03)
Q3 20171($1.08)($1.08)($1.08)
Q4 20171($1.13)($1.13)($1.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Ownership Percentage: 6.50%
Institutional Ownership Percentage: 85.95%
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Trades by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2017William R RingoDirectorSell500$46.73$23,365.00View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.04View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.40View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.52View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.00View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.50View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.00View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.00View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.40View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.56View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.00View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.76View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Five Prime Therapeutics (NASDAQ:FPRX)
Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)
Source:
DateHeadline
nasdaq.com logoFive Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety ...
www.nasdaq.com - July 18 at 12:42 AM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 8:52 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Commences Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in ... - StreetInsider.com
www.streetinsider.com - July 17 at 7:41 PM
finance.yahoo.com logoFive Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
finance.yahoo.com - July 17 at 7:41 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Expected to Announce Quarterly Sales of $10.15 Million
www.americanbankingnews.com - July 16 at 8:28 AM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (NASDAQ:FPRX) Expected to Announce Earnings of -$1.18 Per Share
www.americanbankingnews.com - July 14 at 2:50 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : July 4, 2017
finance.yahoo.com - July 5 at 7:06 AM
finance.yahoo.com logoFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : July 3, 2017
finance.yahoo.com - July 3 at 6:30 PM
marketwatch.com logoFive Prime Therapeutics founder, CEO to step down - MarketWatch
www.marketwatch.com - June 22 at 5:59 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Expected to Post Quarterly Sales of $10.15 Million
www.americanbankingnews.com - June 22 at 11:12 AM
nasdaq.com logoFive Prime's Williams Plans To Transition From CEO To Executive Chairman In 2018
www.nasdaq.com - June 22 at 9:41 AM
finance.yahoo.com logoFive Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : June 22, 2017
finance.yahoo.com - June 22 at 9:41 AM
seekingalpha.com logoFive Prime chief Williams to transition to Executive Chairman; shares ease 1% after hours
seekingalpha.com - June 21 at 6:53 PM
finance.yahoo.com logoFive Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
finance.yahoo.com - June 21 at 6:53 PM
finance.yahoo.com logoFive Prime Therapeutics founder, CEO to step down
finance.yahoo.com - June 21 at 6:53 PM
americanbankingnews.com logoFive Prime Therapeutics, Inc. (FPRX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 7:02 PM
americanbankingnews.com logo-$1.18 EPS Expected for Five Prime Therapeutics, Inc. (FPRX) This Quarter
www.americanbankingnews.com - June 20 at 12:30 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - June 8 at 10:26 PM
seekingalpha.com logoFive Prime Therapeutics (FPRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 6:18 PM
feeds.benzinga.com logoFive Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
feeds.benzinga.com - June 5 at 7:01 PM
seekingalpha.com logoFive Prime Therapeutics updates on FPA144 results - Seeking Alpha
seekingalpha.com - June 5 at 5:22 PM
streetinsider.com logoFive Prime Therapeutics (FPRX) Reports Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:06 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Announces Updated Data From Phase 1 Trial of Single-Agent FPA144 at ASCO ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:06 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - June 4 at 4:20 PM
nasdaq.com logoFive Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 ...
www.nasdaq.com - June 4 at 11:18 AM
finance.yahoo.com logoFive Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting
finance.yahoo.com - June 4 at 11:18 AM
seekingalpha.com logoFive Prime Therapeutics updates on FPA144 results
seekingalpha.com - June 3 at 4:37 PM
globenewswire.com logoFive Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual ... - GlobeNewswire (press release)
globenewswire.com - June 3 at 9:30 AM
finance.yahoo.com logoFive Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
finance.yahoo.com - June 3 at 9:30 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Expected to Post Quarterly Sales of $10.15 Million
www.americanbankingnews.com - May 27 at 9:24 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 6:47 PM
americanbankingnews.com logo Analysts Expect Five Prime Therapeutics Inc (FPRX) Will Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - May 25 at 8:08 AM
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : May 23, 2017
finance.yahoo.com - May 23 at 4:56 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Short Interest Update
www.americanbankingnews.com - May 21 at 11:14 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) ASCO abstract published on phase I/II dose escalation and expansion study of cabiralizumab
www.streetinsider.com - May 18 at 10:06 AM
streetinsider.com logoFive Prime Therapeutics (FPRX) Names Garry Nicholson to Board of Directors - StreetInsider.com
www.streetinsider.com - May 17 at 5:17 PM
finance.yahoo.com logoFive Prime Welcomes Garry Nicholson to Board of Directors
finance.yahoo.com - May 15 at 4:56 PM
seekingalpha.com logoFive Prime Therapeutics At An Attractive Entry Level
seekingalpha.com - May 12 at 10:51 PM
finance.yahoo.com logoETFs with exposure to Five Prime Therapeutics, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 5:55 PM
finance.yahoo.com logoFive Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 5:09 PM
americanbankingnews.com logoJefferies Group Comments on Five Prime Therapeutics Inc's FY2021 Earnings (FPRX)
www.americanbankingnews.com - May 8 at 12:30 PM
globenewswire.com logoFive Prime Announces First Quarter 2017 Results and Provides ... - GlobeNewswire (press release)
globenewswire.com - May 5 at 10:29 PM
finance.yahoo.com logoFive Prime Therapeutics posts 1Q loss
finance.yahoo.com - May 5 at 5:28 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - May 5 at 11:58 AM
seekingalpha.com logoFive Prime Therapeutics' (FPRX) CEO Rusty Williams on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 3:29 AM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Releases Quarterly Earnings Results, Misses Estimates By $0.25 EPS
www.americanbankingnews.com - May 5 at 12:08 AM
finance.yahoo.com logoFive Prime Announces First Quarter 2017 Results and Provides Business Update
finance.yahoo.com - May 4 at 5:27 PM
finance.yahoo.com logoInvestor Network: Five Prime Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:19 PM
americanbankingnews.com logoFive Prime Therapeutics (FPRX) Receives Coverage Optimism Score of 0.33
www.americanbankingnews.com - May 3 at 8:52 PM
americanbankingnews.com logoFive Prime Therapeutics Inc (FPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 3 at 1:11 AM

Social

Chart

Five Prime Therapeutics (FPRX) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff